CompanyHealthEnterprise
Noema Pharma
Noema Pharma is a Basel-based clinical-stage biotech building first-in-disease oral small-molecule therapeutics for central nervous system disorders. Founded in 2019 by Sofinnova Partners around four mid-stage assets in-licensed from Roche, the company targets overlooked neurological conditions - from seizures in tuberous sclerosis complex and pain in trigeminal neuralgia to Tourette syndrome and CNS-mediated symptoms of menopause. It has raised roughly CHF 130 million (about USD 147 million) in Series B financing from a syndicate including Forbion, Jeito Capital, Sofinnova, EQT Life Sciences and UPMC Enterprises.
2019Founded
BaselHQ
CHF 27 million (USD ~25 million), bringing Series B total to CHF 130 million (USD 147 million)Series B extension
biotechcnsneuroscienceclinical-stagerare diseaseorphan disease
